Market Overview:
The global lipid injectable drugs market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The market growth can be attributed to factors such as rising prevalence of chronic diseases, increasing demand for minimally invasive surgeries, and technological advancements in the field of lipid injectable drugs. Based on type, the global lipid injectable drugs market is segmented into intralipid, liposyn III, smoflipid, clinolipid and others. Intralipid held the largest share in 2017 and is expected to maintain its dominance during the forecast period. This can be attributed to its high usage in various applications such as pain reduction, toxicity reduction and targeted drug delivery. Liposyn III is expected to grow at a highest CAGR during the forecast period owing to its growing demand for use in minimally invasive surgeries. Based on application, the global lipid injectable drugs market is segmented into pain reduction, toxicity reduction targetted drug delivery.
Product Definition:
Lipid Injectable Drugs are lipid-based drugs that are injected into the body. They are important because they can be used to deliver drugs and other therapeutic agents directly to the cells. This helps to ensure that the drugs reach their target and have a greater impact.
Intralipid:
Intralipid is a lipoprotein that consists of both phospholipids and cholesterol. It is manufactured by the reaction between human plasma (80%) and alfa-interferon (20%). The drug was developed as an alternative to hydrogel for intravenous lipid emulsions, which are used in the treatment of atheromatosis coliareasepticemia.
Liposyn III:
Liposyn III is a long-acting, high potency, non-esterified sPLA2 inhibitor. It is currently under clinical investigation for the treatment of atopic dermatitis and other chronic skin diseases. Liposyn III has been granted Orphan Drug Designation by the FDA and Fast Track Designation by EMA for its clinical development program in treating atopic dermatitis.
Application Insights:
The pain reduction application segment led the global market in 2017 and is projected to continue its dominance over the forecast period. The rising prevalence of chronic pain disorders, such as neurogenic, arthritic and cancer-related pain, is anticipated to drive the demand for lipid injectable drugs during the forecast period. Moreover, increasing awareness about these benefits among patients as well as healthcare professionals is expected to fuel growth during this timeframe.
The targeted drug delivery application segment accounted for a significant share in 2017 owing to extensive R&D initiatives by various companies including Pfizer Inc., sanofi aventis plc and others for developing novel formulations that are suitable for specific applications such as diabetes or cardiovascular diseases. For instance, Pfizer developed Presbylioskymra liquid which was approved by U.
Regional Analysis:
North America dominated the global market in 2017 owing to favorable reimbursement policies, increasing prevalence of chronic diseases, and rising awareness about advanced technologies. Moreover, presence of key players such as Pfizer Inc.; Johnson & Johnson Services, Inc.; Merck Group; and Sanofi are also contributing towards growth in this region.
Asia Pacific is expected to witness lucrative growth over the forecast period due to factors such as improving healthcare infrastructure coupled with growing target population base especially in India and China. Increasing incidence of diabetes is also anticipated to boost demand for lipid injectable drugs during the forecast period. In addition, rising awareness regarding advanced therapies will further propel regional market development during the forecast period (2018-2030).
In 2016 Novartis AG launched two new products namely Diastol Lipid Solution (D00124).
Growth Factors:
- Increasing prevalence of obesity and metabolic syndrome
- Growing demand for minimally invasive procedures
- Technological advancements in lipid injectable drugs delivery systems
- Rising awareness about the benefits of lipid injectable drugs therapy
- increasing number of clinical studies supporting the use of lipid injectable drugs
Scope Of The Report
Report Attributes
Report Details
Report Title
Lipid Injectable Drugs Market Research Report
By Type
Intralipid, Liposyn III, Smoflipid, Clinolipid, Others
By Application
Pain Reduction, Toxicity Reduction, Targeted Drug Delivery, Others
By Companies
Fresenius Kabi, Abbott Laboratories, Pfizer, B. Braun Melsungen AG, Heron Therapeutics Inc., The Medicines Company (Novartis), Baxter International Inc.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
197
Number of Tables & Figures
138
Customization Available
Yes, the report can be customized as per your need.
Global Lipid Injectable Drugs Market Report Segments:
The global Lipid Injectable Drugs market is segmented on the basis of:
Types
Intralipid, Liposyn III, Smoflipid, Clinolipid, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Pain Reduction, Toxicity Reduction, Targeted Drug Delivery, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Fresenius Kabi
- Abbott Laboratories
- Pfizer
- B. Braun Melsungen AG
- Heron Therapeutics Inc.
- The Medicines Company (Novartis)
- Baxter International Inc.
Highlights of The Lipid Injectable Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Intralipid
- Liposyn III
- Smoflipid
- Clinolipid
- Others
- By Application:
- Pain Reduction
- Toxicity Reduction
- Targeted Drug Delivery
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Lipid Injectable Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Lipid injectable drugs are medications that are injected directly into the fatty tissues beneath the skin. They are used to treat a variety of conditions, including heart disease, high cholesterol, and obesity.
Some of the major players in the lipid injectable drugs market are Fresenius Kabi, Abbott Laboratories, Pfizer, B. Braun Melsungen AG, Heron Therapeutics Inc., The Medicines Company (Novartis), Baxter International Inc..
The lipid injectable drugs market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Lipid Injectable Drugs Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Lipid Injectable Drugs Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Lipid Injectable Drugs Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Lipid Injectable Drugs Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Lipid Injectable Drugs Market Size & Forecast, 2020-2028 4.5.1 Lipid Injectable Drugs Market Size and Y-o-Y Growth 4.5.2 Lipid Injectable Drugs Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Intralipid
5.2.2 Liposyn III
5.2.3 Smoflipid
5.2.4 Clinolipid
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Pain Reduction
6.2.2 Toxicity Reduction
6.2.3 Targeted Drug Delivery
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Lipid Injectable Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Lipid Injectable Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Intralipid
9.6.2 Liposyn III
9.6.3 Smoflipid
9.6.4 Clinolipid
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Pain Reduction
9.10.2 Toxicity Reduction
9.10.3 Targeted Drug Delivery
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Intralipid
10.6.2 Liposyn III
10.6.3 Smoflipid
10.6.4 Clinolipid
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Pain Reduction
10.10.2 Toxicity Reduction
10.10.3 Targeted Drug Delivery
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Intralipid
11.6.2 Liposyn III
11.6.3 Smoflipid
11.6.4 Clinolipid
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Pain Reduction
11.10.2 Toxicity Reduction
11.10.3 Targeted Drug Delivery
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Intralipid
12.6.2 Liposyn III
12.6.3 Smoflipid
12.6.4 Clinolipid
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Pain Reduction
12.10.2 Toxicity Reduction
12.10.3 Targeted Drug Delivery
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Intralipid
13.6.2 Liposyn III
13.6.3 Smoflipid
13.6.4 Clinolipid
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Pain Reduction
13.10.2 Toxicity Reduction
13.10.3 Targeted Drug Delivery
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Lipid Injectable Drugs Market: Competitive Dashboard
14.2 Global Lipid Injectable Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Fresenius Kabi
14.3.2 Abbott Laboratories
14.3.3 Pfizer
14.3.4 B. Braun Melsungen AG
14.3.5 Heron Therapeutics Inc.
14.3.6 The Medicines Company (Novartis)
14.3.7 Baxter International Inc.